Skip to main content

iBio, TheoremDx Collaborating on Dx for Tropical Diseases

NEW YORK (360Dx) – Biopharma firm iBio said today it has partnered with TheoremDx to develop proteins for use in rapid diagnostic testing of tropical diseases.

Under the collaboration, iBio will develop and produce proteins that TheoremDx will use with its point-of-care testing platform to diagnose diseases including the Zika, Dengue, Chikungunya, and West Nile viruses and to develop an improved HIV test.

According to the companies, iBio subsidiary iBio CDMO has worked with TheoremDx over the last six months to develop new processes for engineering proteins for diagnostic purposes and has delivered several proteins for testing.

"Our expression system delivers candidates quickly to TheoremDx and our production system allows rapid, confident cGMP scale-up of production," iBio CDMO President Barry Holtz said in a statement. "This collaboration meets the demands for rapid establishment of new diagnostics."

"TheoremDx has leveraged the flexibility of the iBio system to screen multiple candidate proteins to optimize diagnostic capabilities in our system," said Bruce Batten, chief scientific officer of TheoremDx.

Financial and other terms of the agreement were not disclosed.